- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.11. | Knocked back by the FDA, Biohaven turns to major cost cuts | ||
| 05.11. | Soleno slumps despite sales uptick; Madrigal's MASH drug continues ascent | ||
| 05.11. | Novo narrows sales outlook as GLP-1 price cuts loom | ||
| 05.11. | Braveheart secures $185M to advance challenger to Bristol Myers heart drug | ||
| 04.11. | Blackstone pays Merck $700M to buy into ADC drug royalties | ||
| 04.11. | Metsera again chooses Novo as bidding war with Pfizer intensifies | ||
| 04.11. | Vertex's new pain, blood disorder drugs miss Wall Street expectations | ||
| 04.11. | Sarepta Duchenne drugs come up short in confirmatory test | ||
| 04.11. | Neok Bio launches with $75M to make dual-targeting ADCs | ||
| 03.11. | UniQure dives after FDA's 'very surprising' reversal on Huntington's gene therapy | ||
| 03.11. | Caribou results suggest renewed promise for 'off-the-shelf' cancer cell therapy | ||
| 03.11. | Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark | ||
| 03.11. | Roche taps an AI specialist to craft new brain drugs | ||
| 03.11. | 4 must-have capabilities in a digital health partner in the era of AI | ||
| 31.10. | Lilly quietly cuts a pain drug from its pipeline | ||
| 31.10. | HRSA approves 340B rebate models to hospitals' chagrin | ||
| 31.10. | Corporate venture firms stepped in for drug startups during biotech funding pullback | ||
| 30.10. | Earnings roundup: Alnylam's down day, Neurocrine's head scratch and Biogen's 'low quality' win | ||
| 30.10. | Lilly hikes revenue forecasts on booming obesity drug sales | ||
| 30.10. | FDA places formal hold on two Intellia CRISPR trials | ||
| 30.10. | Novo tops Pfizer with $6.5B bid for Metsera | ||
| 29.10. | FDA, aiming to lower drug costs, moves to speed approval of biosimilars | ||
| 29.10. | Lilly aligns with Walmart in bid to broaden access to discounted Zepbound | ||
| 29.10. | BridgeBio chalks up another win for its rare disease research | ||
| 28.10. | GSK adds to COPD drug push with Empirico deal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .